Graphic abstract

Review Ascites-Derived Organoids: Emerging Models for Drug Resistance and Personalized Therapy Tingting Liu, Fayong Ke, Yixian Wang, Yuan Dang, Qianhui Xu J. Cancer 2026; 17(12): 2154-2168. doi:10.7150/jca.136865 Full text PDF


Graphic abstract

Research Paper Integrative Multi-Cohort and Single-Cell Analyses Identify KIF11 as a Prognostic and Immune-Cold Marker in Lung Adenocarcinoma Wenbin Jia, Zewei Zhao, Chunlan Ning, Jiaqi Zhou, Bowen Liu, Xinchao Li, Yu Zou, Xuchen Cao, Xin Wang, Yue Yu J. Cancer 2026; 17(12): 2137-2153. doi:10.7150/jca.141576 Full text PDF


Graphic abstract

Research Paper Co-targeting Aurora Kinase A and DNA Damage Response Pathways Enhances Apoptotic Cell Death in Cholangiocarcinoma Cells Benchamart Moolmuang, Mathuros Ruchirawat J. Cancer 2026; 17(12): 2126-2136. doi:10.7150/jca.142715 Full text PDF


Graphic abstract

Review Lung Cancer Evolves as an Ecosystem from Niche Dysregulation to Metastasis and Treatment Resistance Jie Wu, Youyi Ding, Peiliang Huang, Yan Chen, Shuo Chen J. Cancer 2026; 17(12): 2103-2125. doi:10.7150/jca.143837 Full text PDF


Graphic abstract

Review The Roles of Vitamins in Cancer Initiation, Progression, and Therapy: Clinical Evidence, Molecular Mechanisms, and Precision Translation Fanglin Liu, Anqi He, Liang Zhou, Yong Xia, Xuyi Wu, Fuyan Xu J. Cancer 2026; 17(12): 2082-2102. doi:10.7150/jca.141758 Full text PDF


Graphic abstract

Research Paper Real-World Experience with Neoadjuvant Treatment for Stage I-III Non-Small Cell Lung Cancer: A Single-Center Cohort Study and TriNetX database Yi-Wen Chen, Cheng-Yen Chuang, Chih-Hung Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Po-Hsin Lee, Tsung-Ying Yang, Jeng-Sen Tseng, Shun-Fa Yang J. Cancer 2026; 17(12): 2071-2081. doi:10.7150/jca.142595 Full text PDF

More ...

Issue 11; 2026

Cover image

Indexed in PubMed and SCI expanded; full texts in Europe PMC. ...


Real-World Experience with Neoadjuvant Treatment for Stage I-III Non-Small Cell Lung Cancer: A Single-Center Cohort Study and TriNetX database

Breakthroughs in immune checkpoint inhibitors (ICIs) are rapidly shifting the treatment paradigm for resectable non-small cell lung cancer (NSCLC) toward neoadjuvant and perioperative strategies. To assess the real-world efficacy and broad applicability of neoadjuvant immunotherapy, we analyzed 62 patients who received neoadjuvant systemic therapy followed by surgery at Taichung Veterans General Hospital between November 2019 and April 2025, dividing ...


Lung Cancer Evolves as an Ecosystem from Niche Dysregulation to Metastasis and Treatment Resistance

The clinical heterogeneity of lung cancer, the continuing divergence between primary and metastatic lesions, and relapse after treatment cannot be fully explained by a linear model of cancer-cell-intrinsic mutation. Most tumor-microenvironment reviews describe a local system at a single time point and rarely follow lung cancer across disease stages and organs. Here, we use the ecosystem as a unifying framework to examine how genetic change, tissue ...

Popup Image